Skip to content

Looking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration

Looking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration - Nerve and muscle ultrasound in SCA3

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53256
Enrollment
60
Registered
2023-07-11
Start date
2023-10-03
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar ataxia type 3

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: SCA3: (1) Adults with a (2) genetically confirmed SCA3 mutation spanning the disease spectrum (i.e., from preclinical mutation carriers to moderate/severe ataxia), and (3) able and willing to sign the informed consent. Healthy controls: Age- and sex-matched healthy controls (without a medical history of neurological disorders), able and willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: Other diseases or conditions associated with neuropathy (e.g., diabetes mellitus, previous exposure to cytostatic drugs, alcohol abuse, inflammatory neuropathy, hereditary neuropathy, etc.) and myopathy (e.g., inflammatory/immune-mediated myopathy, metabolic myopathy, toxic myopathy, muscular dystrophy, myotonia, etc.).

Design outcomes

Primary

MeasureTime frame
Nerve ultrasound: - Cross-sectional areas of the median, ulnar, superficial radial, tibial, and sural nerves. Muscle ultrasound: - Muscle volume, fasciculations, and echo intensity of the geniohyoid, digastric, masseter, sternocleidomastoid, trapezius, biceps brachii, flexor carpi radialis, first dorsal interosseus, rectus abdominis, rectus femoris, tibialis anterior, and medial gastrocnemius muscles.

Secondary

MeasureTime frame
Nerve conduction studies: - Sensory nerve action potential (SNAP) amplitudes and conduction velocities of the median, ulnar, superficial radial, and sural nerves. - Compound muscle action potential (CMAP) ampliitudes, motor nerve conduction velocities, and distal motor latencies of the median, ulnar, and tibial nerves. Plasma neurofilament light chain concentration. Clinical measures / questionnaires: Scale for the Assessment and Rating of Ataxia (SARA), SCA Functional Index (SCAFI), Total Neuropathy Score clinical version, muscle cramp scale (MCS), Cramps Disability Scale (CDS), Friedreich Ataxia Rating Scale Activities of Daily Living (FARS ADL), cerebellar cognitive affective syndrome (CCAS) scale, EQ-5D-5L, Patient Health Questionnaire-9 (PHQ-9), Fatigue Severity Scale (FSS), International Restless Legs Scale (IRLS), Pittsburgh Sleep Quality Index (PSQI), Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia), Personal Questionnaire (PQ), Goal Attainment Scale (GAS), Utrecht Coping List (UCL-P), Utrecht Proactive Coping Competention List (UPCC) and Neuropathic Pain Scale (NPS).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 3, 2026